Dr. Eswar Shankar | Cancer Research | Excellence in Research Award

Assistant Professor (Research) at The Ohio State University, United States

Dr. Eswar Shankar is a dedicated cancer researcher and academic leader, currently serving as Research Assistant Professor at The Ohio State University’s Department of Internal Medicine, Division of Medical Oncology. His work bridges fundamental cancer biology and translational approaches, with a strong emphasis on molecular mechanisms and novel therapeutic strategies.

🧑‍🔬 Profile

Scopus

🏆 Excellence in Research Award

Dr. Eswar Shankar’s outstanding contributions to cancer research, mentorship, and translational innovation make him an exemplary candidate for the Excellence in Research Award. His pioneering studies on epigenetic targets, combinatorial cancer therapies, and metabolic reprogramming in resistant tumors have significantly advanced the field and inspired new clinical strategies.

🎓 Education

Dr. Shankar completed his Ph.D. at Cochin University of Science and Technology, India, and his M.S. in Biochemistry at Annamalai University. He further expanded his expertise through a postdoctoral fellowship at the University of North Texas Health Science Center, USA, specializing in molecular biology and immunology.

💼 Experience

With over two decades of research experience, Dr. Shankar has held key roles including Assistant Research Professor and Research Scientist at Case Western Reserve University and The Ohio State University. His positions have involved leading multidisciplinary teams, mentoring trainees, and driving impactful projects in oncology.

🔬 Research Interests

Dr. Shankar’s research focuses on elucidating signaling pathways in prostate and breast cancers, targeting epigenetic regulators like EZH2, overcoming therapeutic resistance, and advancing combination treatments. His interdisciplinary approach combines molecular biology, systems biology, and translational research to develop innovative cancer therapies.

📚 Publications

Dr. Shankar has contributed extensively to scientific literature, with over 40 peer-reviewed publications spanning high-impact journals.

• “Polyunsaturated fatty acids regulate neurotransmitter contents in rat brain” (2001, Indian J Biochem Biophys).

• “Dopaminergic regulation of insulin secretion” (2006, IUBMB Life).

• “PKC-epsilon protects cells from TNF-mediated death” (2007, Apoptosis).

• “Downregulation of Bid with PKC epsilon-mediated TRAIL resistance” (2007, Cell Death Differ).

• “Resistance of MCF-7 cells to TRAIL via Akt/Hdm2/p53” (2008, Oncogene).

• “Chamomile: Herbal medicine with bright future” (2010, Mol Med Rep).

• “Role of PKC epsilon in Bcl-2 activation” (2010, Int J Oncol).

• “Betulinic acid induces apoptosis in prostate cancer” (2017, Molecules).

• “MiR-644a disrupts oncogenic transformation” (2019, Cancer Res).

• “Green tea-induced epigenetic reactivation in prostate cancer” (2019, Mol Carcinog).

• “Inhibition of Wnt/β-catenin pathway in prostate cancer resistance” (2023, Mol Carcinog).

• “Development of apigenin prodrug for cancer” (2024, J Biomol Struct Dyn).

• Plus recent editorial: “Adopting drug repurposing to overcome drug resistance” (2023, Front Cell Dev Biol).

His publications highlight advanced insights into cancer signaling, resistance mechanisms, and natural product therapeutics, cementing his reputation as a leader in cancer research.